<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158174">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044393</url>
  </required_header>
  <id_info>
    <org_study_id>1334.10</org_study_id>
    <secondary_id>2013-003814-42</secondary_id>
    <nct_id>NCT02044393</nct_id>
  </id_info>
  <brief_title>Interaction of BI 691751 With Itraconazole</brief_title>
  <official_title>Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the relative bioavailability of a single dose of BI 691751 when given alone
      and together with itraconazole; safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 up to the last quantifiable data point)</measure>
    <time_frame>31 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte of BI 691751 in plasma and whole blood)</measure>
    <time_frame>31 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>31 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose BI 691751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of itraconazole + single dose BI 691751</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>multiple doses of itraconazole given as capsules</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>single dose BI 691751 given as tablet</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>single dose BI 691751 given as tablet</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

          2. body mass index (BMI) of 18.5 to 29.9 kg/m2

          3. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

          1. Any finding in the medical examination (including blood pressure (BP), pulse rate
             (PR), or electrocardiogram (ECG)) deviating from normal and judged clinically
             relevant by the investigator.

          2. Pulse rate outside 45 to 100 bpm or repeated measurements of systolic BP outside 90
             to 140 mmHg or diastolic BP outside 50 to 90 mmHg.

          3. Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance

          4. Any alanine transaminase (ALT/GPT), aspartate transaminase (AST/GOT), or
             gammaglutamyltransferase (GGT) value outside the reference range at the screening
             examination

          5. Any evidence of a concomitant disease judged clinically relevant by the investigator

          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          7. Any history of relevant liver diseases such as disturbance of liver function,
             jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver
             tumors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1334.10.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
